{"id":"ipp-201101","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As an investigational immunopharmaceutical from ImmuPharma, IPP-201101 is being developed to modulate immune function. The specific molecular mechanism and target remain proprietary or not fully disclosed in public literature, though the company's focus suggests potential application in autoimmune or oncologic indications where immune modulation is therapeutically relevant.","oneSentence":"IPP-201101 is an immunomodulatory compound designed to enhance immune responses against disease targets.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:49.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02504645","phase":"PHASE3","title":"A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"ImmuPharma","startDate":"2015-03","conditions":"Lupus Erythematosus, Systemic","enrollment":202},{"nctId":"NCT03427151","phase":"PHASE3","title":"Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"ImmuPharma","startDate":"2018-02-27","conditions":"Lupus Erythematosus, Systemic","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lupuzor, regiremod"],"phase":"phase_3","status":"active","brandName":"IPP-201101","genericName":"IPP-201101","companyName":"ImmuPharma","companyId":"immupharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}